Patents by Inventor Kamal U. Saikh

Kamal U. Saikh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Small molecule inhibitor of MYD88 for therapeutic treatment against alphavirus and staphylococcal enterotoxin infections and toxin exposure
    Patent number: 9833437
    Abstract: A synthetic molecule 4210 and a therapeutic use of a synthetic small molecule 4210 for treating viral infections, especially encephalitic alphavirus infections. The compound 4210 showed antiviral efficacy by up regulation type 1 interferon (IFN) specifically IFN-?. The compound 4210 was designed and synthesized by a structure-based approach targeting intracellular adaptor protein, myeloid differentiation primary response protein 88 (MyD88). Besides having an antiviral effect, the compound 4210 also demonstrated therapeutic efficacy for treating inflammatory syndrome associated with Gram positive bacterial infections such as exposure to staphylococcal enterotoxin B (SEB) induced toxic shock syndrome (TSS) in mice and can potentially be used in clinical set up for treating sepsis and septic shock.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: December 5, 2017
    Assignee: The United States of America as represented by the Secretary of the Army
    Inventors: Kamal U Saikh, Julius M. Rebek, Jr., Pamela J Glass
  • Small Molecule Inhibitor of MYD88 For Therapeutic Treatment against Alphavirus And Staphylococcal Enterotoxin Infections And Toxin Exposure
    Publication number: 20170079952
    Abstract: A synthetic molecule 4210 and a therapeutic use of a synthetic small molecule 4210 for treating viral infections, especially encephalitic alphavirus infections. The compound 4210 showed antiviral efficacy by up regulation type 1 interferon (IFN) specifically IFN-?. The compound 4210 was designed and synthesized by a structure-based approach targeting intracellular adaptor protein, myeloid differentiation primary response protein 88 (MyD88). Besides having an antiviral effect, the compound 4210 also demonstrated therapeutic efficacy for treating inflammatory syndrome associated with Gram positive bacterial infections such as exposure to staphylococcal enterotoxin B (SEB) induced toxic shock syndrome (TSS) in mice and can potentially be used in clinical set up for treating sepsis and septic shock.
    Type: Application
    Filed: December 5, 2016
    Publication date: March 23, 2017
    Applicant: The Government of the United States, as represented by the Secretary of the Army
    Inventors: Kamal U. Saikh, Julius M. Rebek, JR., Pamela J. Glass